SDC1 and colonic neoplasm: Shed syndecans have been demonstrated to be plausible biomarkers for predicting cancer progression in some studies, namely elevated serum levels of syndecan-1 are associated with a poor prognosis in bladder cancer, cervical cancer, and colon cancer, among others [117,118,119,120,121].